Auragens
Leading The Way In Ethical, Scientifically-Backed Stem Cell Therapy
Dr. Daniel S. Briggs, President
STEM Cell Treatment Center
A specialized healthcare provider focused on regenerative medicine using stem cell–based therapies to support tissue repair, pain management, and treatment of degenerative or chronic conditions. These centers combine clinical expertise, laboratory science, and personalized treatment protocols to deliver innovative, minimally invasive therapeutic solutions across orthopedic, neurological, aesthetic, and wellness applications.
Solutions
The science surrounding stem cells dates back over a century, but their clinical applications are relatively young. While stem cell therapy and regenerative medicine hold immense promise, the field remains vulnerable to misinformation, pseudoscience and bad actors who exploit hope without ensuring safety or delivering results. As these treatments gain popularity in wellness circles, the gap between public perception and clinical reality widens.
State of Industry
Navigating the Therapeutic Divide in Stem Cell Medicine
Regenerative medicine is driven by two distinct therapeutic models—autologous and allogeneic stem cell therapies—which share the goal of tissue repair but differ fundamentally in sourcing, manufacturing, and clinical use. Autologous therapies utilize a patient's own cells, which are harvested, often modified or expanded ex vivo, and then reintroduced into the same individual. In contrast, allogeneic therapies rely on cells sourced from a healthy donor, which are processed and stored for "off-the-shelf" use in multiple recipients. This foundational difference dictates their respective advantages in clinical outcomes, scalability, and patient-specific applications, positioning them not as direct competitors but as complementary strategies addressing different clinical needs and market segments.
Deep Dive
What Sets a Stem Cell Treatment Center Apart
Stem cell treatment has moved from fringe curiosity to a serious point of interest for healthcare leaders, athletes, private patients and institutions exploring regenerative care. That growth has also created a difficult buyer environment. The market includes advanced clinical teams, loosely verified providers and companies selling biologic products with uneven transparency. Executives evaluating a stem cell treatment center cannot rely on reputation, patient stories or broad wellness language alone. The stronger question is whether the center can explain what it administers, why it is appropriate for a specific patient and how it tracks results after treatment.
Leadership Perspective
University of Pennsylvania Health System
Cell Therapies: Here comes the next wave!
Robert Richards, Corporate Director of the Center for Cell Therapy and Transplant, Penn Medicine
Robb Richards has over 20 years of experience in oncology, first with a private practice in Southern New Jersey and more recently the University of Pennsylvania Health System. He has served in different roles throughout his healthcare career: IT Manager for the Center for Cancer and Hematologic Disease in Cherry Hill, Division Chief Operating Officer of Regional Cancer Care Associates (RCCA) in Cherry Hill, New Jersey, and RCCA corporate VP and Chief Information Officer. He unofficially joined Penn’s Cell Therapy and Transplant program (CTT) in 2016 and was the lead in overseeing the operationalizing/implementation of CAR T cell therapy for commercial use. Currently, he is the Corporate Director of The Center for Cell Therapy and Transplant program at Penn Medicine, overseeing commercial and research work and its expansion into community hospitals within the Penn system. He also assists other disease groups within the organization as they are onboarding gene therapies.
